

NEONATAL Medication Monograph

AMPHOTERICIN LIPOSOMAL (Ambisome®)

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires Microbiologist review within 24 hours of initiation

A HIGH RISK Medication

Confusion between the formulations of amphotericin deoxycholate (Fungizone®) and liposomal amphotericin (Ambisome ®) may result in errors, both of prescribing and administration. These medications are **NOT** interchangeable

Presentation	Vial: 50mg				
Fresentation					
	Infusion solution from Pharmacy				
Description	Polyene antifungal				
Indications	Treatment of invasive fungal infections by susceptible fungi including Candida spp., Aspergillus spp. and Cryptococcus species. Candida lusitaniae and A. terreus are resistant.				
Dosado	١V·				
Dosaye	Initial daga 1mg/kg/daga				
	miliai dose – mg/ kg/ dose				
	Maximum dose: 5mg/ kg/ dose				
Interactions	Increased risk of nephrotoxicity if used concurrently with other				
	nephrotoxic drugs e.g. aminoglycosides, vancomycin.				
	Flucytosine toxicity may be enhanced				
	Corticosteroids and diuretics may enhance the hypokalaemic effect				
	of amphotericin B				
Compatible Fluids	Glucose 5%				

Preparation	IV: Available from CIVAS (KEMH & PCH)		
Troparation	 Step 1 - Reconstitution Add 12mL of Water for Injection to 50mg vial. Shake for at least 30 seconds. Concentration =4mg/mL Filter reconstituted solution using supplied filter, prior to dilution. 		
	Step 2 - Dilution Take 5mL (20mg) of above filtered solution and make up to 10mL with Glucose 5%.		
Administration	IV Infusion: Infuse over 60-120 minutes		
	IV line must be flushed with 5% glucose before and after the dose		
Monitoring	Urine output. Full blood count (FBC) for anaemia and thrombocytopenia		
	Renal function (for elevated creatinine), electrolytes (for hypokalaemia) and liver function (for derangements of liver enzymes).		
	Monitor serum concentrations of concomitant nephrotoxic drugs.		
Adverse Reactions	Common: nausea, vomiting, rash, fever, rigors		
	Serious: hypokalaemia, hypomagnesaemia, hypocalcaemia, nephrotoxicity, anaemia, thrombocytopenia		
Storage	Vial: Store at room temperature, below 25°C		
	Reconstituted solution : Stable for 24 hours at 2–8°C. Discard unused portion after 24 hours.		
	Do not use the reconstituted solution or infusion if cloudy or a precipitate is present. Protect from light.		
Notes	If infusion-related immediate reactions occur (e.g. fever, hypotension), duration of infusion may be increased to 3–4 hours.		
	Liposomal amphotericin B is considered to be at a lower risk of causing harm if extravasated (as compared to amphotericin B – conventional).		
	If total parenteral nutrition (TPN) or IV fluids are turned off during the infusion, consider monitoring of blood glucose.		
	Cerebrospinal fluid (CSF) penetration of lipid formulations of amphotericin B is poor.		
	Ensure adequate hydration		

References	Ainsworth SB. Neonatal formulary 7: drug use in pregnancy and the first year of life. Seventh ed. Chichester (West Sussex): John Wiley & Sons Inc.; 2015. p140	
	Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2401. 2, p141-142.	
	Truven Health Analytics. Amphotericin Liposomal. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Sept10]. Available from: https://neofax.micromedexsolutions.com/	
	Society of Hospital Pharmacists of Australia. Amphotericin Liposomal. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Sept10]. Available from: <u>http://aidh.hcn.com.au</u>	
	Lilley L, Legge D. Paediatric injectable guidelines. 5th ed. Melbourne (Victoria): The Royal Children's Hospital; 2019.	
	Paediatric Formulary Committee. BNF for Children: 2017. London: BMJ Group Pharmaceutical Press; 2017	

Keywords:	Amphotericin, liposomal, fungal, ambisome				
Publishing:	Intranet Internet				
Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	August 2002	Version:	3.0		
Last reviewed:	October 2019	Next review date:	Oct 2022		
Endorsed by:	Neonatal Directorate Management Group	Date:	Oct 2019		
Standards Applicable:	Applicable: NSQHS Standards: 1 Covernance, 3 Infection Control, 4 Medication Safety, 8 Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled.					
Access the current version from the WNHS website.					
For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au					

© Department of Health Western Australia 2019